

FOSUN PHARMA
复星医药

2023



1

2

3

4

5

6



414.00

(-5.81%YoY)

+ 12.43%YoY

mRNA

PD-1

HER2

(

)

59.37

(+0.88%YoY)

43.46

+1.02%YoY

34.14

(-19.05%YoY)

23.86

(-36.04%YoY)

6.83

2

1

Gland Pharma

20.11

(-48.08%YoY)

5.47

3.37

2.64

Cenexi



2023

2/2

2023	2022
414.00	439.52
198.05	207.82
47.8%	47.3%
97.12	91.71
23.5%	20.9%
24.4%	26.4%
43.75	38.28
10.6%	8.7%
43.46	43.02

2023

1/2



PD-1

2023 11.20 (+230.20%)

3 ES-SCLC ES-SCLC PD-1

9 ESCC

12 ES-SCLC



Argesun

6 WHO PQ 21

#

2 P-CAB DU RE 2024 1 *

#

6 2024 1 *

#

5 CKD SHPT

#

8

#

6 r/r LBCL

#

3 2021

#

3 2019



ES-SCLC
ESCC
P-CAB
DU
RE
CKD

SHPT
r/r LBCL
MAA
nsNSCLC
BLA
NF1

B

#

*

2023 9 30



® PD-1

3 ES-SCLC MAA EMA

11 nsNSCLC NDA



HER2

2023 27.49 +58.19%YoY

2 BLA FDA

RT002

#

1)

2

4

7

Profhilo

#

11

Tenapanor

#

CKD

7

FCN-437c

CDK4/6

HR

HER2

11

FS-1502

HER2-ADC #

HER2

3

III

13

4

III

2

ET-26

10

III

FCN-159 MEK

1

2

4

7

/

NF1



6

GT1-GT6 Go/No Go

TRC Translational Research Center

SAB Scientific Advisory Board

8 FDA HER2
Pre-License Inspection

10 FDA
Pre-Approval Inspection

Gland Pharma 3 FDA GMP

10 GMP GMP
12 GMP

12 PD-1 ES-SCLC
4 CD20 16
Boston Oncology 8 PD-1 Kgbio
12 10 PD-1
Intas 4200

Sisram
Gland Pharma 4 Cenexi

12 Insightec

HER2 (PD-1)

2024 1 *

Xi 12 10

2024 3 Ion
*





HLX-10 (PD-1)
HLX-22 (HER-2)

ADC

FS-1502 (HER-2 ADC)
HLX-43 (PD-L1 ADC)
HLX-42 (EGFR ADC)

XS-02 (CHK1)
XS-03 (PLK1)
FCN-159 (MEK1/2)
FH2001 (FGFR/VEGFR)



(CD20)
HLX-15 (CD38)

FKC-876 (CD19-CAR-T)
FKC-889 (CD19-CAR-T)
GCK-01 (CAR-NK)

XS-04



VS-S103 (GLP1)

Tenapanor (ESRD-HD)
XH-S004



CNS

ET-26 (GABA)
Opicapone (COMT)



FKC-288
(CAR-T)
XH-S003 (Factor B)



13
24

2023年		 / ADC	
	 () (DU) (RE) )  (CKD)) SHPT )	 1 ES-SCLC 9 ESCC 12 Zerpidio	 r/r LBCL  Vero *
/	NDA/BLA ) FCN-437c(CDK4/6 2L)) Tenapanor() Opicapone() Pretomanid XDR MDR-TB III FCN-437c(CDK4/6 1L)) FCN-159(MEK1/2) SAF-189(ALK) ALK+ ET-26	NDA/BLA  NDA  MAA EMA ) BLA FDA RT002 Prothilo III /  ES-SCLC / FS-1502 HER2-ADC HER2 HLX04-O VEGF wAMD HLX11 HER2 HLX14 RANKL OP	III / 13 III  r/r iNHL FK889 r/r MCL B r/r ALL
/	FCN-159(MEK1/2) / NF1 I 7 4	HLX208 BRAFV600E LCH Erdheim-Chester ECD HLX42 EGFR ADC EGFR EGFR	 r/r iNHL

*

2023 9 30




2023 103.71

Gland Pharma	CDMO	4	Cenexi
10			
Intas	4200		



5 800



5 16 GPO

PD-1

ES-SCLC

PD-1

Sisram

2016 36% 12 2022 66% 6 2023 78%

2023 61.1% 2022 57.0%

2023 9 30

M SCI ESG
ESG

A
CSR

ESG



2023
+19%YoY

1.3
10,114
2,879,342
+110%YoY
100%

1,056
+7%YoY



Argesun
eCME
ESG

10
3.4
18
49.53%
4
8
WHO PQ
6,800
39.7%



ESG
ESG
ESG
ESG
ESG
ESG
ESG
ESG
ESG
ESG





3400+

70+

48,000L

100+

600+

9

FDA

GMP




~5,000

~1,000



-





2023

SCLC

PD-1

11.20



PD-1

MSI-H

sqNSCLC

ES-SCLC

ESCC

ES-SCLC

SCLC FDA EC

ES-SCLC

ES-SCLC

MAA

EMA



ES-SCLC

III

(OS)

OS

15.4

10.9

24

43.1%

7.9%

JAMA

Nature Medicine

British Journal of Cancer



580

PD-1

8

PD-1

KGbio

12

10

2023 6 [r/r LBCL](#)

CAR-T

2023

10

4

5 10

4

VERO

3 5

8


()

1 3

34



2023





1 P-CAB




PEG



HFrEF

20%
21%




NK-1 5-HT3

96h

CINV
96.6%

CINV
97.6%
86%



3~4

III 7

(PTH)
23

FGF23

III

8
95.8%
6
94.4%

*

*

RT-002

-

1)

4

7

FDA

9

2

6



ET-26

-

10

III

FS-1502

-


HER2

Gland
Pharma







1



2,3



3



2022
2023

Sisram

Breas /

10

CT

2024 3 lon NMPA *

2023

Series

T

PCR-

F-A7000

- 1
 - 2
 - 3
- 1
- 2




Sisram

2023 9 30



*

Sisram
100

78%



Soprano Titanium
BeautiFill
Opus
FDA
LipoSense
CellFie



lon

2024 3 lon *




lon

lon

lon







2022
2023




1


2

2023

6,548 * 8





2023 9 30



2023	4,411	8.47%
2023	1,302	7.75%
	C	2023
8.22%		357



1			2019 2 2 RA	3 RA	1	
2			1 HER2 Phoenix S.A.	2 Accord Healthcare Limited	3 PT Kalbio Global Medika Laboratoro ELEA 40	
3			PD-1 1 2023 CSCO CSCO	2022 3 MSI-H CSCO	2 CSCO 9	3 PD-1 
4			2020 12 1	2 GMP	3 4	
5		*	2020 4		ITP	

6		*	2021 8 PDE4	4	
7		*	2019 8 NK-1 5-HT3		
8		*	2023 6	1	
9		T *	SOT		
10			2021 6 1 12 B B CAR-T r/rDLBCL r/rLBCL	2	
11					

12		*	2023 5 SHPT	CKD	
13		*	P-CAB 2023 2 DU/RE P-CAB 1 DU RE	2024 3 26	
14			Artesun Artesun SPAQ-CO + D-ARTEPP 1 2023 12 33 WHOPQ Artesun 2023 6 WHOPQ 21 2023 12 3.4		
15		*	RNA 2022 7	HIV-1	
16		mRNA *	(mRNA BNT162b2) (/Omicron BA.4-5) XBB1.5 5 11 6 4	XBB1.5 Omicron	
17		Vero	Vero 2016 9 (Vero) CIN1v, 2024 3 (vero)	1.0ml 1 1.0ml	

18			0.5ml/2009 72005 110.25ml/ WHO13	
19				
20		*	2023 8 (NYHAI-IV IVEF< 40%)	

			/			IND	1	2	3	NDA
HLX10 ¹	+		PD-1	/		III	2022	11		
						2022	FDA/EC	2023	1	
	+ +		PD-1			III	2023	1		
	+HLX07		PD-1+EGFR							
+HLX07 +		PD-1+EGFR +VEGF								
+HLX208 [#]		PD-1+BRAFV600E	BRAFV600E BRAFV600							
HLX07			EGFR							
HLX22 [#]	+		HER2							
	+	+	HER2+ PD-1 +HER2							
HLX11			2	HER2		III				
HLX05			3	EGFR						
HLX02			4	HER2		FDA	2020			
FS-1502 [#]		-	HER2	HER2						
			HER2	HER2						
		+	PD-1	HER2						

				/			IND	1	2	3	NDA
	HLX26	+		LAG-3+PD-1	mCRC						
		+	+								
				-	LAG-3						
	HLX15			CD38		2023	2				
	HLX51			OX40							
	HLX13			CTLA-4							
	HLX53			TIGIT							
	HLX60		-	GARP							
		+		GARP+PD-1			I				
	HLX42			EGFR	/		FDA				
	HLX43			PD-L1	/						
	VT-101										
SurVaxM [#]			Survivin								
	(	T	)	-	GvHD						
			50R	INSR							
			25R	INSR							
			GLP-1								
			GLP-1		2024	I	*				
			INSR								
HLX04-O ¹			VEGF		2022	2	III				
HLX14	2		RANKL		2022	6	III	2022	7	TGA	III
RT002 [#]				GL	2023	4					
				CD	2023	7					
GC101			COL7A1 CGT								

1/2

		/			IND	1	2	3	NDA
FCN-437c		CDK4/6	2L						
			1L						
SAF-189		ALK/ROS1	ALK+						
			ROS1+						
HLX208 [#]	-	BRAF	Erdheim-Chester ECD LCH	2023 4 LCH ECD NMPA					
	+	BRAF+PD-1	BRAFV600E BRAFV600						
FCN-159		MEK1/2	I	2023 7 NMPA				II	
				2023 4 NMPA					
YP01001		VEGFR							
FCN-338	+	BCL-2							
	-			I					
	-		B	I					
FH-2001		FGFR/VEGFR							
XS-03		PLK1	RAS						

2/2

		I			IND	1	2	3	NDA
	#	TPO-R	ITP						
Tenapanor #		NHE3	CKD						
				2023 7 NDA NMPA					
Tenapanor #		NHE3	(IBS-C)		I				
Pretomanid #		-	XDR-TB / MDR-TB					Pretomanid*	
OP0595(Nacubactam) # +		-							
Opicapone #		COMT			Ongentys*				
Fortacin #		-			*				
ET-26		-			2023 10		III		
FCN-159		MEK1/2							
SZEY-2108		-	CRE		2023 6 NMPA				
XH-S002		FXIa							
FCN-016		ROCK			2023 1 NMPA				
XH-S003		Factor B	IgA		I	2024 3	I		

			IND	1	2	3	NDA



/

T



CHO



/ /


VERO

/

mRNA



-



	2023 1
	8 ESG

1/2

4+7		5mg	3
		10mg	1
		250mg	3
		150mg	3
		2.5mg	3
		100mg	4
		40mg	2
		100mg	3
		1mg/2mg	3
		250mg	2
		10mg	3
		40mg	5
	2	10mg	4
	1	500mg	1
		200mg	2
		20mg	5
		250mg	1

2/2

D			
	D	□	4
		50mg	4
		10ml/3ml	5
	(30R)	10ml	7
	(30/70)	3ml	6
	(50R)	3ml	8
		1g/0.25g/0.5g/2g	4
		0.25g/0.5g/1g	2
		5ml/10ml/20ml	2

1

LOGO

Fosun Pharma, the Representor



www.fosunpharma.com